Jun 19, 2025
Dr. Chuck Link is the Executive Chairman of Syncromune, a company developing a novel immunotherapy approach for solid tumors by delivering the therapy into the tumor and surrounding lymph nodes to stimulate a systemic immune response. Their complex drug has four different components with varying levels of activity that...
Jun 19, 2025
Dr. Chuck Link is the Executive Chairman of Syncromune, a company developing a novel immunotherapy approach for solid tumors by delivering the therapy into the tumor and surrounding lymph nodes to stimulate a systemic immune response. Their complex drug has four different components with varying levels of activity that...
May 27, 2025
Rob Armstrong, CEO of Artax Biopharma, highlights the basic mechanism of action of Nck modulators and how they differ from traditional immunosuppressant drugs to treat autoimmune diseases. Taking this adjustable thermostat approach aims to modulate the immune response rather than completely suppressing the response,...
May 27, 2025
Rob Armstrong, CEO of Artax Biopharma, highlights the basic mechanism of action of Nck modulators and how they differ from traditional immunosuppressant drugs to treat autoimmune diseases. Taking this adjustable thermostat approach aims to modulate the immune response rather than completely suppressing the response,...
Feb 24, 2025
Jeffrey Meckler, CEO of Indaptus Therapeutics, is focused on using their decoy platform to activate the immune system to fight cancer and infections. This approach activates the innate and adaptive pathways in a controlled manner using a short-term pulsed dosing regimen and helps avoid the toxicity issues seen in...